Generex Biotechnology Corporation

615 articles with Generex Biotechnology Corporation

• Generex Biotechnology Announces Investor Conference Call Scheduled for Friday February 5, 2021 at 9:00 AM

  1/8/2021

  Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) today announced that it will hold an investor conference call on Friday February 5, 2021 at 9:00 AM. Joseph Moscato, Generex President & Chief Executive Officer stated: “I am excited to give our first shareholder conference call to update investors about the development of our Ii-Key complete vaccine against the SARS-CoV-2 coronavirus that continues to ravage the world. We

• Generex and NuGenerex Immuno-Oncology Provide Update on Ii-Key COVID-19 Vaccine Development Program and Files Trademark Application for The Complete Vaccine™

  12/31/2020

  Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that its majority owned public entity, NuGenerex Immuno-Oncology, Inc. (NGIO), has filed for and expects to receive a trademark for The Complete Vaccine™

• Generex and NuGenerex Immuno-Oncology Ii-Key-SARS-CoV-2 Vaccine Partner Bintai Kinden Executes its Exclusive Distribution & Licensing Option for Australia and New Zealand

  11/23/2020

  Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) and subsidiary NuGenerex Immuno-Oncology today announced that their Ii-Key COVID-19 vaccine development partner Bintai Kinden Corporation and its subsidiary BINTAI HEALTHCARE SDN.

• Generex signs Worldwide Licensing Deal with China Partners on the Development of an Ii-Key-H1 Swine Influenza Vaccine

  11/19/2020

  Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that the company has signed a worldwide Licensing and Development Agreement with a consortium of partners in China to utilize the Ii-Key vaccine platform technology from Generex subsidiary NuGenerex Immuno-Oncology (NGIO) for developing a vaccine against the G4 EA H1N1 swine influenza that is rapidly emerging in China.

• Generex Inks $50 Million Licensing Deal with China Partners on the Cooperative Development of the Ii-Key Vaccine Platform

  11/18/2020

  Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that the company has closed a $50 million Licensing and Development Agreement with a consortium of partners in China for the Ii-Key vaccine platform technology from Generex subsidiary NuGenerex Immuno-Oncology (NGIO)

• Generex Biotechnology Announces Interview with Richard Purcell EVP of R&D on the Yo! Dr.Yo Show with an Update on the Ii-Key COVID Vaccine ProgramLivestream Interview on Friday November 13 at 2 PM EST

  11/12/2020

  Generex Biotechnology Corporation (OTCQB:GNBT) today announced that Richard Purcell, Executive Vice President of Research & Development at Generex and NuGenerex Immuno-Oncology will be featured on the Yo! Dr. Yo Show to provide an update on the company’s COVID-19 vaccine development program.

• Generex Announces the Signing of a Framework Agreement with The China CDC, Beijing Guoxin Haixiang Equity Investment Partnership and Beijing Youfeng International Consulting Co., Ltd on the Cooperative Development of Ii-Key Vaccines

  11/4/2020

  Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the company has signed a Framework Agreement with the China CDC, Beijing Guoxin Haixiang Equity Investment Partnership, and Beijing Youfeng International Consulting Co., Ltd for the development and commercialization of the Ii-Key-SARS-CoV-2 coronavirus vaccine in China.

• NuGenerex Immuno-Oncology Announces the Launch of a New Corporate Website

  11/3/2020

  NuGenerex Immuno-Oncology (NGIO), a subsidiary of Generex Biotechnology Corporation pleased to announce that the company has launched its new corporate website to provide investors with information on the NGIO mission, management, and pipeline for the Ii-Key vaccine platform for cancer and infectious disease.

• Generex Subsidiary NuGenerex Immuno-Oncology Announces Appointment of Dr. Tamera Coyne-Beasley to the Scientific Advisory Board for its COVID-19 Vaccine Development Program

  10/30/2020

  -Dr. Tamera Coyne-Beasley, MD, MPH, FAAP, FSAHM is the Derrol Dawkins, MD Endowed Chair in Adolescent Medicine at Children’s of Alabama, Professor of Pediatrics and Internal Medicine, Director of the University of Alabama at Birmingham Division of Adolescent Medicine, and Vice Chair of Pediatrics for Community Engagement

• Generex Biotechnology Announces Corporate Update and Investor Conference Call: NuGenerex Immuno-Oncology on Thursday October 8, 2020 at 8:00 AM

  10/7/2020

  Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced call-in details for tomorrow’s investor conference call on Thursday October 8, 2020 at 8: 0 0 AM Eastern time . The access information for the investor conference call is as follows: Domestic US/Canada – 1 - 877-830-2587 Direct Toll / International - 1- 785-424-1734 Program Title: NuGenerex Immuno- Oncology -  Investor Conference Call Conference I

• Generex Biotechnology Subsidiary NuGenHealth Contracts with Paradise Valley Family Medicine to Provide Chronic Care Management (CCM) and Remote Patient Monitoring (RPM) Services

  9/25/2020

  Generex Biotechnology Corporation (OTCQB:GNBT) announces that its newly formed subsidiary NuGenHealth has signed a contract with Paradise Valley Family Medicine (PVFM) to provide connected care solutions for patient engagement, Remote Patient Monitoring (RPM) and Chronic Care Management (CCM) services.

• Generex Signs Binding Licensing & Research Agreement with Bintai Kinden to Advance the Clinical Development & Commercialization of Ii-Key-SARS-CoV-2 Coronavirus Vaccine for Malaysia

  9/18/2020

  Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that the company and Bintai Kinden Corporation of Malaysia have signed an addendum binding the terms of the previously signed Memorandum of Understanding for the development and commercialization of the Ii-Key-SARS-CoV-2 coronavirus vaccine.

• Generex Biotechnology Announces Analyst Report by Ari Zoldan at Seeking Alpha

  9/9/2020

  Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced that an independent analyst report by Ari Zoldan was published on Seeking Alpha, a crowd-sourced content service for financial markets.

• Generex Biotechnology Announces Call-in Details and Updated Agenda for Shareholder Conference Call on Wednesday, August 26th, 2020 at 9:30 AM Eastern

  8/26/2020

  Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced that the company’s wholly owned subsidiary NuGenerex Health LLC has signed a joint venture agreement with Worldwide Digitech, LLC (WWDT) to form NuGenHealth LLC

• Generex Biotechnology Announces New Updated Agenda for Shareholder Conference Call on Wednesday August 26th, 2020 at 9:30 AM

  8/25/2020

  The access information for the investor conference call remains as follows: Direct Toll / International – 1-(866) 831-8711 Domestic US/Canada - 1-(203) 518-9883 Program Title: Generex Biotechnology Conference Call Conference ID – 89636 Updated Agenda FDA response to Pre-IND briefing package for Ii-Key-SARS-CoV-2 vaccine Meeting with the Canadian National Research Council to discuss moving the Ii-Key-SARS-CoV-2 vaccine technology forward Completed the deal with Worldwide Digitech, LLC (

• Generex Biotechnology Announces Call-in Details and Updated Agenda for Shareholder Conference Call on Wednesday August 26th, 2020 at 9:30 AM

  8/25/2020

  Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced the call in information and an updated agenda for the shareholder conference call on Wednesday, August 26th at 9:30 am.

• Generex Biotechnology Updates Agenda for Shareholder Conference Call on Wednesday August 26th, 2020 at 9:30 AM

  8/19/2020

  Letter of Intent (LOI) signed with potential partners in China to develop the Ii-Key-SARS-CoV-2 vaccine for China with a proposed $5 million upfront payment upon contract signing and minimum of $400 million if the vaccine is proven successful in clinical trials. $20 Million Memorandum of Understanding completed with an investor for a strategic upmarket transaction, including a $10 Million financing proposal for the acquisition of infectious disease and cancer diagnostics company awaiting EUA a

• Generex Signs a Memorandum of Understanding with Bintai Kinden to Advance the Clinical Development & Commercialization of Ii-Key-SARS-CoV-2 Coronavirus Vaccine for Malaysia

  8/18/2020

  Bintai Kinden Corporation Berhad ( www.bintai.com.my ) is an investment holding company headquartered in Malaysia with operations throughout South-East Asia, China, and the Arabian Gulf Region Upfront development payment 100% funding for commercial registration of Ii-Key- SARS-CoV-2 prophylactic vaccine against COVID-19 in Malaysia Licensing fees upon approval Potential $150 million in GNBT revenues for vaccine sales in Malaysia MIRAMAR, Fla., Aug. 18, 2020 (GLOBE NEWSWIRE) -- This pr

• Generex Announces Signed Agreement with Bintai Kinden to Advance the Clinical Development & Commercialization of Ii-Key-SARS-CoV-2 Coronavirus Vaccine for Malaysia

  8/18/2020

  Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced that the company has signed a memorandum of understanding with Bintai Kinden Corporation of Malaysia for the development and commercialization of the Ii-Key-SARS-CoV-2 coronavirus vaccine.

• Generex Biotechnology Announces Agenda for Shareholder Conference Call on Wednesday August 26th, 2020 at 9:30 AM

  8/17/2020

  $20 Million Memorandum of Understanding completed with an investor for a strategic upmarket transaction $10 Million financing proposal in the same MOU for the acquisition of infectious disease and cancer diagnostics company awaiting EUA approval from FDA for COVID-19 rapid diagnostic assay system ALTuCELL acquisition update NuGenHealth SaaS Remote Patient Monitoring and Chronic Care Management 50% Partnership Completed a Memorandum of Understanding Regarding Development partnership for Ii-Ke